Current Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B

Soon Sun Kim, Jae Youn Cheong, and Sung Won Cho

Department of Gastroenterology, Ajou University School of Medicine, Suwon, Korea

Although the prevalence of chronic hepatitis B has decreased considerably in recent years due to widespread use of the hepatitis B virus (HBV) vaccine, its prevalence still remains high in adults, and this can place a significant burden on health care in areas with endemic HBV. Since the introduction of nucleos(t)ide analogues (NUCs), there has been marked improvement in the care of patients with chronic hepatitis B, resulting in increased survival. However, the emergence of drug resistance in patients treated with NUCs is a major concern. The number of multi-drug resistant patients is increasing, and many patients may not respond to the currently available drugs. In this review, we describe the current status of NUC therapy for antiviral-naive and -resistant patients.

Key Words: Chronic hepatitis B; Nucleos(t)ide analogue; Drug resistance; Hepatitis B virus

INTRODUCTION

Chronic hepatitis B virus (HBV) infection is an important health problem affecting approximately 400 million people worldwide. Chronic HBV infection can progress to cirrhosis, decompensated cirrhosis, hepatocellular carcinoma (HCC), and death. The prevalence of HBV infection has decreased dramatically following widespread use of HBV vaccine in Korea, an endemic area. However, chronic HBV infection is still prevalent in the population in their 20s in Korea,¹ and has remained a significant burden to the health care system. The circulating level of HBV DNA has been proved as the most important correlating factor in the development of cirrhosis and HCC. The suppression of HBV replication can reduce necroinflammatory activity and prevent progression to cirrhosis and HCC. Several nucleos(t)ide analogues (NUCs) have been developed over the past decade, and the administration of NUCs has played a crucial role in the treatment of chronic HBV infection. Despite their potent anti-HBV effects, NUCs cannot eradicate HBV infection, and for this reason, long-term therapy is necessary. The major drawback of long-term monotherapy with NUCs is the emergence of drug resistance. The emergence of resistance limits the efficacy of the antiviral drugs, raising a serious concern in clinical practice. The prevention of drug resistance and selection of appropriate treatment options in the face of drug resistance are important for reducing morbidity and mortality of patients with chronic HBV infection.

GOALS OF TREATMENT

The goal of therapy is to improve survival by preventing progression of chronic hepatitis to cirrhosis, end-stage liver disease or HCC. Short-term goals include reduction in HBV DNA levels, persistent alanine aminotransferase (ALT) normalization, and hepatitis B e antigen (HBeAg) seroconversion. Loss of hepatitis B surface antigen (HBsAg) is an ideal end point, but this rarely occurs. NUCs can not completely eradicate HBV infection as they show little effectiveness in eliminating covalently closed circular DNA in the nucleus of infected hepatocytes. Long-term administration on NUCs is required in order to effectively treat patients with chronic HBV infection.

The European Association for the Study of the Liver (EASL) guidelines suggest that therapy must reduce HBV DNA to as low a level as possible, ideally below the lower limit of detection by the real-time PCR assay.² Persistent viremia has been associated with frequent development of antiviral resistance.

DEFINITION OF FAILED RESPONSE AND VIRAL RESISTANCE

1. Primary non-response

Primary non-response is defined as less than a 1 log₁₀IU/mL.
decrease in HBV DNA level from baseline after 3 months of therapy based on the EASL guidelines. The American Association for the Study of Liver Disease (AASLD) guidelines define primary non-response as failure to achieve a $2 \log_{10} \text{IU/mL}$ decrease in HBV DNA after at least 6 months of therapy (Table 1). It may be due to poor compliance or low antiviral activity. A switch to a more potent drug is recommended for patients with primary non-response.

2. Partial response

The EASL guidelines propose that partial virologic response is defined as a decrease in HBV DNA of more than $1 \log_{10} \text{IU/mL}$ but detectable HBV DNA by real time PCR at week 24 or 48, depending on the genetic barrier of anti-viral drugs (Table 1). If drugs with a high genetic barrier such as entecavir (ETV) or tenofovir (TDF) are being administered, antiviral response can be assessed at week 48. Adefovir (ADV) has delayed antiviral effect. Thus, these patients can also be assessed at week 48. A partial virologic response to antiviral drugs correlates with the risk of promoting antiviral resistance. The serum HBV DNA level at week 24 of therapy was found to be associated with the emergence of antiviral resistance in patients treated with telbivudine (LdT) or lamivudine (LAM). Patients with HBV DNA level >1,000 copies/mL at week 24 of therapy correlated with high rates of resistance when compared to those with a low HBV DNA level. A prospective cohort study of untreated hepatitis B patients showed that the risk for cirrhosis and HCC was higher in patients with HBV DNA levels >10,000 copies/mL compared to those with HBV DNA <10,000 copies/mL. International practice guidelines recommend treating chronic hepatitis B patients with HBV DNA levels >10,000 copies/mL using antiviral drugs. When partial virologic response is identified, antiviral treatment should be modified.

3. Virologic breakthrough

Virologic breakthrough is defined as an increase in serum HBV DNA by $>1 \log_{10} \text{IU/mL}$ above nadir after achieving a virologic response during treatment (Table 1). Drug non-compliance is frequently associated with virologic breakthrough. Therefore compliance should be confirmed at the time of virologic breakthrough. If virologic breakthrough occurs, serum HBV DNA increases progressively despite continuous treatment followed by an elevation in ALT level. A test for genotypic resistance is needed to confirm the diagnosis and select appropriate treatment options. For patients presenting with mild elevation in HBV DNA and normal ALT, additional tests for HBV DNA are also necessary.

**NUCLEOS(T)IDE ANALOGUES**

A number of NUCs have been developed and used for the treatment of patients with chronic HBV infection. NUCs inhibit viral polymerase activity, thus affecting negative strand and positive strand DNA synthesis. LAM, an analogue of dideoxycytidine, was the first approved HBV polymerase inhibitor. LAM is the prototype of the L-nucleoside family. The triphosphate form of LAM inhibits nascent viral DNA synthesis. Other NUCs belonging to the L-nucleoside family are emtricitabine, LdT, and clevudine. ADV and TDF belong to the acyclic D-nucleotide, while ETV to the cyclic D-nucleoside. ADV and TDF are phosphorylated forms of nucleotide analogues. Long-term administration of drugs belonging to the L-nucleoside family is associated with the frequent development of antiviral resistance, when compared to drugs belonging to D-nucleos(t)ide analogues (Table 2).

**Table 1. Definition of a Response to Antiviral Therapy for Chronic Hepatitis B**

|                          | AASLD*                  | EASL†                  | APASL‡                  |
|--------------------------|-------------------------|------------------------|-------------------------|
| Primary non-response     | Decrease in serum HBV DNA by $<2 \log_{10} \text{IU/mL}$ after at least 24 weeks of therapy | Decrease in serum HBV DNA less than $1 \log_{10} \text{IU/mL}$ from baseline at 3 months of therapy | Reduction of serum HBV-DNA $<1 \log_{10} \text{IU/mL}$ at 12 weeks of oral antiviral therapy in a compliant patient |
| Partial virological       |                         |                         |                         |
| response                 |                         |                         |                         |
| Virological breakthrough | Increase in serum HBV DNA by $>1 \log_{10} (10\text{-fold})$ above nadir after achieving virologic response, during continued treatment | Increase in serum HBV DNA level of more than $1 \log_{10} \text{IU/mL}$ but detectable HBV DNA by real-time PCR assay§ | $>1 \log_{10} \text{IU/mL}$ increase in serum HBV-DNA from nadir of initial response during therapy as confirmed 1 month later |

*American Association for the Study of Liver Disease guidelines, Hepatology 2009;50:661-662; †European Association for the Study of the Liver guidelines, J Hepatol 2009;50:227-242; ‡Asian-Pacific Association for Study of the Liver recommendations, Hepatol Int 2008;2:263-283; §Partial virologic response should be assessed at 24 weeks of treatment for lamivudine and telbivudine and 48 weeks of treatment for entecavir, adefovir and tenofovir.
Lamivudine (LAM), the (-) enantiomer of 3'-thiacytidine, is an oral 2', 3'-dideoxynucleoside that inhibits DNA synthesis by terminating the nascent proviral DNA chain. Unlike other dideoxynucleosides, LAM does not inhibit mitochondrial DNA or bone marrow progenitor cells at concentrations that block the synthesis of HBV DNA, and it is not incorporated into mitochondrial DNA. The recommended dose of LAM for adults with normal renal function (creatinine clearance >50 mL/min) and no HIV co-infection is 100 mg orally once daily. Dose reduction is necessary for patients with renal insufficiency (Table 3).

In HBeAg-positive chronic hepatitis B patients, HBeAg seroconversion at 1 year was seen in 16-18% of patients who received LAM compared with 4-6% of untreated controls. Undetectable serum HBV DNA was noted in 44-60% of patients, and ALT normalization was observed in 41-72%. Histologic improvement defined as a reduction in the necroinflammato-

### Table 2. Potency and Resistance of Currently Available Nucleos(t)ide Analogues

| Antiviral potency | Genetic barrier | Resistant pattern |
|-------------------|----------------|------------------|
| Pyrimidine analogues |               |                  |
| L-nucleosides     |               |                  |
| Lamivudine         | Moderate       | Low              | rtM204V/I, rtL180M |
| Emtricitaine       | Low            | Low              | rtM204V/I, rtL180M |
| Telbivudine        | High           | Low              | rtM204I          |
| Clevudine          | High           | Low              | rtM204I          |
| Purine analogues   |               |                  |
| Cyclic D-nucleoside|               |                  |
| Entecavir          | High           | High             | rtM204V/I, rtL180M plus rtT184, rtS202, rtM250 |
| Acyclic D-nucleotides|            |                  |
| Adefovir           | Low            | Moderate         | rtA181T/V, rtN236T |
| Tenofovir          | High           | High             | rtA181T/V, rtN236T |

### Table 3. Adjustment of Adult Dosage of Nucleos(t)ide Analogues in Accordance with Creatinine Clearance

| Creatinine clearance (mL/min) | Recommended dose |
|-------------------------------|------------------|
| Lamivudine                    |                  |
| ≥50                           | 100 mg qd        |
| 30-49                         | 100 mg first dose, then 50 mg qd |
| 15-29                         | 35 mg first dose, then 25 mg qd |
| 5-14                          | 35 mg first dose, then 15 mg qd |
| <5                            | 35 mg first dose, then 10 mg qd |
| Adefovir                      |                  |
| ≥50                           | 10 mg qd         |
| 20-49                         | 10 mg every other day |
| 10-19                         | 10 mg every third day |
| Hemodialysis patients         | 10 mg every week following dialysis |
| Entecavir                     | NA naïve         |
| ≥50                           | 0.5 mg qd        |
| 20-49                         | 0.25 mg qd or 0.5 mg q48 hr |
| 10-19                         | 0.15 mg qd or 0.5 mg q 72 hr |
| <10 or Hemodialysis* or CAPD  | 0.05 mg qd or 0.5mg q 7 days |
| Telbivudine                   |                  |
| ≥50                           | 600 mg qd        |
| 30-49                         | 600 mg q 48 hr   |
| <30 (not requiring dialysis)  | 600 mg q 72 hr   |
| End-stage renal disease       | 600 mg q 96 hr*  |
| Tenofovir                     |                  |
| ≥50                           | 300 mg q 24 hr   |
| 30-49                         | 300 mg q 48 hr   |
| 10-29                         | 300 mg q 72-96 hr|
| <10 with dialysis             | 300 mg q 7 days or after a total of approximately 12 hr of dialysis |
| <10 without dialysis          | No recommendation |

This table was adapted from AASLD guidelines (Hepatology 2009;50:661-662).1

CAPD, continuous ambulatory peritoneal dialysis.

*Administer after hemodialysis.
In HBeAg-negative chronic hepatitis B patients, undetectable serum HBV DNA at one year is observed in 60-70% of patients who received LAM. Factors associated with increased durability of LAM-induced HBeAg seroconversion were: longer duration of therapy after HBeAg seroconversion, younger age, a lower HBV DNA level when treatment was stopped, and genotype B versus C. Mutations in the YMDD motif (rtM204V, rtM204I) are the primary mutants responsible for LAM resistance. The other mutations such as rtL180M, rtL80I/V, and rtV173L are frequently found in LAM-resistant patients. A phase III trial showed no ADV-resistant mutations were found after 1 year of treatment, but cumulative probabilities of genotypic resistance to ADV at 1, 2, 3, 4, and 5 years were 0%, 3%, 11%, 18%, and 29%, respectively in HBeAg-negative patients. The cumulative rate of genotypic resistance to ADV was estimated to be 20% after 5 years of treatment in HBeAg-positive patients. Risk factors for ADV resistance include suboptimal viral suppression and sequential ADV monotherapy in LAM-resistant patients. In LAM-resistant patients, the cumulative genotypic resistance and virologic breakthrough at 5 years of sequential ADV monotherapy were reported to be 65.6% and 61.8%, respectively.

### 3. Entecavir

Entecavir (ETV) is a carbocyclic analogue of 2'-deoxyguanosine. It can inhibit HBV replication at three different steps: the priming of HBV DNA polymerase, the reverse transcription of the negative strand HBV DNA from the pregenomic RNA, and the synthesis of the positive strand HBV DNA. The approved dose of ETV for nucleoside-naïve patients is an oral dose of 0.5 mg daily and 1.0 mg for LAM-refractory/resistant patients. The dose should be adjusted for patients with an estimated creatinine clearance <50 mL/min (Table 3).

In HBeAg-positive patients, ETV resulted in significantly higher rates of virologic, histologic, and biochemical responses compared to LAM. In a Phase III clinical trial, serum HBV DNA was undetectable at 1 year in 67% of patients who received ETV 0.5 mg compared to 36% of patients who received LAM 100

---

9-11
12,13
17,18
20-22
23
24,25
26
28,29
30
31
32,33
65.6% and 61.8%, respectively in HBeAg-negative patients. The rtA181T/V and rtN236T mutations are associated with ADV resistance. In vitro studies have shown that ADV-resistant mutations decrease susceptibility to treatment by 3 to 15 folds. A phase III trial showed no ADV-resistant mutations were found after 1 year of treatment, but cumulative probabilities of genotypic resistance to ADV at 1, 2, 3, 4, and 5 years were 0%, 3%, 11%, 18%, and 29%, respectively in HBeAg-negative patients. The cumulative rate of genotypic resistance to ADV was estimated to be 20% after 5 years of treatment in HBeAg-positive patients. Risk factors for ADV resistance include suboptimal viral suppression and sequential ADV monotherapy in LAM-resistant patients. In LAM-resistant patients, the cumulative genotypic resistance and virologic breakthrough at 5 years of sequential ADV monotherapy were reported to be 65.6% and 61.8%, respectively.

### 3. Entecavir

Entecavir (ETV) is a carbocyclic analogue of 2'-deoxyguanosine. It can inhibit HBV replication at three different steps: the priming of HBV DNA polymerase, the reverse transcription of the negative strand HBV DNA from the pregenomic RNA, and the synthesis of the positive strand HBV DNA. The approved dose of ETV for nucleoside-naïve patients is an oral dose of 0.5 mg daily and 1.0 mg for LAM-refractory/resistant patients. The dose should be adjusted for patients with an estimated creatinine clearance <50 mL/min (Table 3).

In HBeAg-positive patients, ETV resulted in significantly higher rates of virologic, histologic, and biochemical responses compared to LAM. In a Phase III clinical trial, serum HBV DNA was undetectable at 1 year in 67% of patients who received ETV 0.5 mg compared to 36% of patients who received LAM 100
mg. Histologic improvement was observed in 72% and 62% of patients and ALT normalization was observed in 68% and 60% of patients, respectively. HBcAg seroconversion rates were also seen in 21% of patients who received ETV compared to 18% of patients who received LAM.\textsuperscript{45} ETV resulted in earlier and more marked viral suppression than ADV.\textsuperscript{46} In HBeAg-negative patients, ETV resulted in significantly higher rates of virologic, histologic and biochemical responses compared to LAM. More patients in the ETV group had undetectable serum HBV DNA levels (90% vs 72%) and normalization of ALT levels (78% vs 71%) compared to that of the LAM group. Histologic improvement after 48 weeks of treatment occurred in 70% as compared with 61% of patients in the LAM group. The mean reduction in serum HBV DNA levels from baseline to week 48 was greater with ETV than with LAM (5.0 vs 4.5 \log_{10} \text{copies/mL}).\textsuperscript{47} In decompensated cirrhosis, a recent study showed that ETV resulted in virologic and biochemical responses similar to the compensated liver disease group. Undetectable serum HBV DNA was observed in 89.1% of the decompensated group compared to 78.5% of the compensated group. HBcAg seroconversion rate (48.1% vs 41.1%) and normalization of ALT (76.4% vs 75.0%) were also similar between the two groups.\textsuperscript{45}

In HBeAg-positive patients who lost HBeAg and discontinued ETV therapy after 48 weeks, undetectable HBV DNA, normalization of ALT and HBcAg seroconversion were sustained in 39%, 79%, and 77%, respectively, at 24 weeks off-treatment.\textsuperscript{42} However in HBeAg-negative patients, only 3% sustained suppression of serum HBV DNA to undetectable levels at 24 weeks after cessation of treatment.\textsuperscript{43}

Resistance to ETV appears to occur through a two-hit mechanism with initial selection of the rtM204V/I mutation, followed by amino acid substitutions at rtT184, rtS202, or rtM250. In NUCs-naïve patients, the 5-year cumulative probability of genotypic ETV resistance and genotypic ETV resistance associated with virologic breakthrough was only 1.2% and 0.8%, respectively. In contrast, the 5-year cumulative probability of genotypic ETV resistance was 51% and 43%, respectively, in LAM-resistant patients.\textsuperscript{44} In vitro studies showed that ETV-resistant mutations are susceptible to ADV and TDF.\textsuperscript{45}

4. Telbivudine

Telbivudine (LdT), a synthetic thymidine nucleoside analogue (L-enantiomer of thymidine), is phosphorylated intracellularly to the active triphosphate form, which competes with the natural substrate thymidine 5'-triphosphate to inhibit hepatitis B viral DNA polymerase; this enzyme inhibition blocks reverse transcriptase activity, thereby reducing viral DNA replication. The approved dose of LdT is 600 mg daily. Doses should be adjusted for patients with estimated creatinine clearance <50 mL/min (Table 3).

In HBeAg-positive patients, LdT resulted in significantly higher rate of virologic and histologic responses compared to LAM. In a phase III clinical trial, undetectable serum HBV DNA at 1 year was observed in 60.0% of patients who received LdT 600 mg compared to 40.4% of patients who received LAM 100 mg. Histologic improvement was observed in 64.7% and 56.3% of patients, respectively. However, there was no significant difference in biochemical and serologic response rates. ALT normalization was observed in 77.2% of patients who received LdT compared to 74.9% of patients who received LAM, and similar results were observed in HBcAg seroconversion rates, 22.5% for LdT group and 21.5% for LAM group.\textsuperscript{46} After 2 years of treatment, LdT resulted in higher rate of sustained undetectable serum HBV DNA rates (55.6% vs 38.5%) and ALT normalization (69.5% vs 61.7%) compared to LAM. The HBcAg seroconversion rate was similar in two groups (29.6% vs 24.7%).\textsuperscript{47} In HBeAg-negative patients, LdT showed a significantly higher rate of virologic response when compared to LAM. Undetectable serum HBV DNA levels at 1 year were observed in 88.3% of patients who received LdT, compared with 71.4% of patients treated with LAM. Results of histologic improvement and ALT normalization were similar in two groups: 66.6% vs 60.0% and 74.4% vs 79.3% after 1 year of LdT and LAM treatment, respectively.\textsuperscript{46} After 2 years of treatment, LdT sustained a higher rate of undetectable serum HBV DNA (82.0% vs 56.7%) and similar ALT normalization rate (77.8% vs 70.1%) compared to LAM. Non-detectable serum HBV DNA at treatment week 24 was the strongest predictor for better outcomes for both HBeAg-positive and HBeAg-negative patients.\textsuperscript{48} In Korean patients, similar antiviral effectiveness of LdT was observed in a subgroup analysis of GLOBE phase III clinical trial.\textsuperscript{49}

LdT selects for mutations in the YMDD motif. The rtM204I mutation was the primary basis for LdT resistance, with secondary mutations detected at the rtL80, rtL180, and other codons. The rtA181T mutation was detected in several LdT recipients but was not associated with viral breakthrough and it was replaced by wild type with continued LdT treatment in most patients.\textsuperscript{50} In the phase III clinical trial, genotypic resistance after 1 and 2 years of treatment was observed in 5.0% and 25.1% of HBeAg-positive and in 2.3% and 10.8% of HBeAg-negative patients who received LdT, compared to 11.0% and 39.5% of HBeAg-positive and 10.7% and 25.9% of HBeAg-negative patients who received LAM, respectively.\textsuperscript{46} In vitro studies have shown that HBV with the rtM204I mutation remains sensitive to the nucleotide analogues, ADV and TDF.\textsuperscript{50} This is supported by the fact that switch or add-on ADV treatment reduced serum HBV DNA levels by 3.7 to 4.3 logs in 16 weeks, indicating that viral suppression can be restored by switch-to or add-on ADV.\textsuperscript{47}

5. Tenofovir

Tenofovir disoproxil fumarate (TDF), an oral prodrug of tenofovir, is a nucleotide analogue with potent activity against HBV DNA polymerase. It is similar to ADV in structure and in vitro
studies have shown that TDF and ADV are equipotent. Since TDF appears to be less nephrotoxic, the approved dose is much higher than ADV; 300 mg vs 10 mg daily. The dose should be adjusted for patients with estimated creatinine clearance <50 mL/min (Table 3).

In HBeAg-positive patients, TDF 300 mg resulted in significantly higher rate of undetectable serum HBV DNA (76% vs 13%), ALT normalization (68% vs 54%), and HBsAg loss (3% vs 0%) compared to ADV 10 mg at 1 year. TDF showed similar rate of histologic response (74% vs 68%) and HBsAg seroconversion (21% vs 18%) compared to ADV.51 After 3 years of TDF treatment, including some patients who received 1-year ADV treatment followed by 2-year TDF treatment, 72% of HBeAg-positive patients had undetectable serum HBV DNA levels. ALT normalization was seen in 81%, HBsAg loss occurred in 34% and HBsAg seroconversion was observed in 26% of patients. HBsAg loss over 3 years was 8%.51 In HBeAg-negative patients, TDF resulted in higher rate of undetectable serum HBV DNA than ADV (93% vs 63%). Histologic improvement and ALT normalization were similarly observed in two groups (72% vs 69% and 76% vs 77%, respectively).51 After 3 years of TDF treatment, including some patients who received 1 year of ADV treatment followed by 2 years of TDF treatment, 87% of HBsAg-negative patients had undetectable serum HBV DNA levels. ALT normalization was observed in 74% of patients. No patient achieved HBsAg loss up to 3 years.52 In patients with decompensated liver disease, a phase II study showed tolerability failure was as infrequent as 6.7% in the TDF group, 4.4% in the TDF plus emtricitabine group, compared to 9.1% in ETG group (p=0.622). At week 48, serum HBV DNA <400 copies/mL was observed in 70.5% of the TDF group, 87.8% of the TDF plus emtricitabine group, and 72.7% of the ETG group. ALT normalization was observed in 57%, 76%, and 55% of patients and HBsAg seroconversion occurred in 21%, 13%, and 0% of patients, respectively. Child-Turcotte-Pugh and Modification for End-stage Liver Disease scores improved in all groups.

In HBeAg-positive patients, TDF 300 mg resulted in significantly higher rate of undetectable serum HBV DNA (76% vs 13%), ALT normalization (68% vs 54%), and HBsAg loss (3% vs 0%) compared to ADV 10 mg at 1 year. TDF showed similar rate of histologic response (74% vs 68%) and HBsAg seroconversion (21% vs 18%) compared to ADV.51 After 3 years of TDF treatment, including some patients who received 1-year ADV treatment followed by 2-year TDF treatment, 72% of HBeAg-positive patients had undetectable serum HBV DNA levels. ALT normalization was seen in 81%, HBsAg loss occurred in 34% and HBsAg seroconversion was observed in 26% of patients. HBsAg loss over 3 years was 8%.51 In HBeAg-negative patients, TDF resulted in higher rate of undetectable serum HBV DNA than ADV (93% vs 63%). Histologic improvement and ALT normalization were similarly observed in two groups (72% vs 69% and 76% vs 77%, respectively).51 After 3 years of TDF treatment, including some patients who received 1 year of ADV treatment followed by 2 years of TDF treatment, 87% of HBsAg-negative patients had undetectable serum HBV DNA levels. ALT normalization was observed in 74% of patients. No patient achieved HBsAg loss up to 3 years.52 In patients with decompensated liver disease, a phase II study showed tolerability failure was as infrequent as 6.7% in the TDF group, 4.4% in the TDF plus emtricitabine group, compared to 9.1% in ETG group (p=0.622). At week 48, serum HBV DNA <400 copies/mL was observed in 70.5% of the TDF group, 87.8% of the TDF plus emtricitabine group, and 72.7% of the ETG group. ALT normalization was observed in 57%, 76%, and 55% of patients and HBsAg seroconversion occurred in 21%, 13%, and 0% of patients, respectively. Child-Turcotte-Pugh and Modification for End-stage Liver Disease scores improved in all groups.51 TDF monotherapy was found to induce potent and long lasting antiviral response in NUCs-experienced patients with previous treatment failure (LAM, ADV, LAM plus ADV).54

One study reported that alanine to threonine substitution at rtA194 was associated with resistance to TDF in patients with HBV and HIV co-infection.55 A recent study has found that the rtA194T polymerase mutation is associated with partial TDF drug resistance and negatively impacts the replication competence of HBV constructs. However, viral replication can be restored to wild type levels if these polymerase mutations occur together with precore or basic core promoter substitutions, as found in HBeAg-negative hepatitis B.56 A phase III clinical trial reported that none of the amino acid substitutions in HBV DNA polymerase/reverse transcriptase that developed through 3 years of treatment were associated with decreased phenotypic sensitivity to TDF.57

6. Clevudine

Clevudine [1-(2-deoxy-2-fluoro-b-Larabinofuranosyl) thymine, L-FMAU] is a nucleoside analog with an unnatural 3-L configuration and has shown potent effect against HBV and some activity against Epstein-Barr virus in vitro. Clevudine inhibits the DNA-dependent DNA activity of HBV polymerase, as well as reverse transcription and priming. Clevudine has no effect on mitochondrial DNA metabolism at concentrations ranging from 0.1 to 200 μM, as measured by lactic acid production, mitochondrial DNA content and structural effects.57-59 The approved dose of clevudine is 30 mg daily orally.

In HBeAg-positive patients, 59.0% in the clevudine group had undetectable serum HBV DNA levels (less than 300 copies/mL) at week 24. The proportion of patients who achieved normalization of ALT levels was 68.2% in the clevudine group and 17.5% in the placebo group. HBsAg loss and seroconversion occurred in 15.3% and 10.0% of patients in the clevudine group at week 48. These rates were similar to those in the placebo group (12.0% and 12.0%, respectively).59 Compared with LAM, clevudine demonstrated greater virologic, serologic, and biochemical responses. Median reduction in serum HBV DNA at week 48 was 4.27-5.2 log10 copies/mL compared to 3.17-4.2 log10 copies/mL in the LAM group. Undetectable serum HBV DNA was observed in 60-73% and 38-40% in the clevudine and LAM group, respectively. HBeAg seroconversion occurred in 11-18% of patients in the clevudine group compared with 11-12% in the LAM group at week 48.60,62 In HBeAg-negative patients, 92.1% in the clevudine group had undetectable serum HBV DNA levels at week 24. The proportion of patients who achieved ALT normalization was 74.6% and 33.3% in clevudine and placebo groups at week 24, respectively.63

However, in contrast to published data on the safety profile of clevudine based on short-term clinical trials, several studies reported relatively frequent chances of developing myopathy in patients who received longer therapy with clevudine. A recent study reported the emergence of myopathy in 32 patients (8.8%) out of 363 chronic hepatitis B patients receiving clevudine therapy for more than 6 months.64 Myopathy associated with clevudine is characterized by a weakness in proximal muscles of the lower extremities with elevated muscle enzymes, presumably caused by mitochondrial toxicities.64

Virologic breakthrough occurred in 0-5.5% up to 1 year treatment with clevudine.59,61 In vitro phenotypic analysis showed that the mutation rtM204I was predominantly associated with clevudine resistance, whereas rtL229V was a compensatory mutation for the impaired replication of the rtM204I mutant. A study of 14 clevudine-resistant patients showed rtM204I in 85% of the patients, and rtA181V and rtA181T were each observed in 1 patient.65 All of the clevudine-resistant clones were resistant to LAM.56
TREATMENT OF NAÏVE PATIENTS

Drugs with potent antiviral activity and a high genetic barrier (ETV or TDF) should be used for NUCs-naïve patients. The rate of partial response assessed at week 48 was 45% in HBeAg-positive naïve patients receiving ETV. However, 83% and 89% of HBeAg-positive patients achieved HBV DNA levels <300 copies/mL at week 96 and 144, showing long-lasting antiviral effect of ETV.40

LAM was widely prescribed for patients with chronic hepatitis B owing to its antiviral efficacy and safety profile. Nonetheless, since LAM induces high rate of resistance, it is not recommended as first-line therapy. Switching from LAM to ETV monotherapy may be considerable. A study about the efficacy of ETV monotherapy in LAM-pretreated patients showed that HBV DNA suppression (<2.6 log10 copies/mL) was achieved in 100% and 92% of patients after 2 years of ETV switching therapy according to baseline HBV DNA levels (less than 2 and 2-5.0 log10 copies/mL, respectively).40 Thus, switching to ETV should be considered in LAM-pretreated patients. Switching to TDF may have similar effects in this setting of patients.

A favorable long-term response was found in some patients receiving LAM or LdT. A 5-year follow-up study showed that 90% of patients with two baseline factors (HBV DNA levels <9 log10 copies/mL, ALT ≥2xULN) and with week 24 HBV DNA of <3 log10 copies/mL achieved HBeAg seroconversion, and 10% of them had YMDD mutations.40 The GLOBE trial showed that HBeAg-positive patients with baseline HBV DNA of <9 log10 copies/mL, ALT ≥2xULN and non-detectable HBV DNA at 24 weeks of LdT therapy achieved HBeAg seroconversion in 52%, and LdT resistance in 1.8% at 2 years of therapy.48 These results suggest that patients with non-detectable HBV DNA at 24 weeks of LAM or LdT therapy would have a good response to long-term treatment with those drugs.

TREATMENT OF DRUG RESISTANT PATIENTS

In the past, LAM was widely used for the treatment of chronic hepatitis B patients, and resistance to LAM developed in many patients. The development of LAM resistance limits future treatment options. Sequential monotherapy with ADV or ETV for LAM resistance was associated with the frequent development of dual resistance to LAM and ADV or ETV. To avoid development of multi-drug resistance, add-on therapy has been recommended for anti-viral drug resistance. Drugs that are not cross-resistant should be used for add-on therapy. It was reported that virologic breakthrough developed in 8 of 80 (10%) NUCs-naïve and 12 of 27 (44%) LAM-pretreated patients after 12 months of clevudine therapy.47 Thus, clevudine therapy should not be considered for LAM-pretreated patients.

ADV add-on to ongoing LAM is the standard therapy for patients with LAM resistance. An Italian cohort study showed that none developed ADV resistance during a median of 40 months of treatment duration in patients with ADV added to LAM, whereas virologic breakthrough due to mutations developed in 21% of patients receiving ADV monotherapy.73 Add-on therapy was found to be more efficacious in patients receiving early treatment with ADV than in patients receiving treatment later at the time of high viremia levels.72

ADV monotherapy is still used in some patients with LAM resistance because of the high cost of add-on therapy. In patients with LAM-resistant HBV, ADV monotherapy had been an established treatment modality for several years, but recent studies have reported that it carries a significant risk for resistance in the long term.71,72 Virologic and biochemical breakthrough with the emergence of ADV-resistant mutations occurred in 21% of patient who received ADV monotherapy at 15 to 18 months of treatment.71 Another study has reported that ADV resistance reached 6% at week 192 in patients with HBV DNA <3 log10 copies/mL at week 48 of ADV monotherapy, compared with 49% at same time point in patients with HBV DNA >3 log10 copies/mL at week 48 of ADV monotherapy. These were HBeAg-negative patients with LAM resistance.70 Thus, continuation of ADV monotherapy may maintain undetectable HBV DNA levels in patients with a complete response to ADV monotherapy. However, LAM should be added to ongoing ADV therapy in patients with only a partial virologic response to ADV monotherapy. Later addition of LAM to ADV monotherapy was found to effectively prevent the development of ADV resistance in patients with LAM resistance, comparable to the ADV addition to ongoing LAM therapy.72 LAM-resistant mutants remain susceptible to TDF, and TDF has a more effective anti-HBV effect than ADV. TDF add-on therapy may be more effective in preventing the development of resistance than ADV add-on in LAM-resistant patients.

Sequential ADV monotherapy for LAM resistance increases the development of multi-drug resistance to LAM and ADV, and resistance to LAM and ADV occurs even in LAM-resistant patients receiving combination therapy with LAM and ADV. ADV-resistant mutants remain sensitive to TDF or ETV. Sequential TDF monotherapy was report to completely suppress HBV DNA only in a minority of patients with dual drug resistance to LAM and ADV.75 Recently, a prospective study showing efficacy of TDF rescue therapy for patients with failure of both LAM and ADV has been reported. Forty-six percent and 64% of patients with failure of both LAM and ADV (suboptimal response or genotypic resistance) achieve an undetectable HBV DNA at 48 and 96 weeks of TDF therapy, suggesting that TDF is the preferred drug in patients with prior failure or resistance to LAM and ADV. However, antiviral activity of TDF was found to be inferior to that observed in naïve-patients and in previous studies.76 Combination therapy with ETV and TDF has been recommended for the treatment of patients with resistance to LAM and ADV.70 The efficacy of sequential ETV monotherapy was found to be
suboptimal in these patients.\textsuperscript{77,78} ETV monotherapy selected YMDD mutants in all patients within 48 weeks of therapy, resulting in early development of ETV resistance.\textsuperscript{77} The efficacy of combination therapy with LAM and ADV was compared with ETV monotherapy in these patients. Combination therapy with LAM and ADV was shown to be inferior to ETV monotherapy in suppressing HBV DNA.\textsuperscript{79} However, drug resistance developed more frequently in patients receiving ETV monotherapy than patients receiving LAM plus ADV at 18 months of therapy.\textsuperscript{80} ETV-resistant mutations are susceptible to TDF and ADV. TDF add-on therapy is recommended for ETV resistance by EASL and AASLD guidelines. ADV add-on therapy should be considered in ETV-resistant patients. However, the efficacy of ADV add-on therapy may be limited in ETV-resistant patients.

\section*{CONCLUSIONS}

The development of NUCs represents a significant advance in the treatment of chronic hepatitis B. Long-term treatment with NUCs has improved liver function and increased survival of patients. However, their major action is to suppress HBV replication, rather than eliminate HBV completely. The limitations are a higher chance of relapse after discontinuation of treatment and emergence of anti-viral resistance. Drugs with strong antiviral effect and a high genetic barrier to mutation, such as ETV and TDF, are recommended for the treatment of naïve-patients. The emergence of antiviral resistance limits treatment options. Add-on therapy with drugs without cross-resistance is a rule for drug resistance. Treatment options may be limited due to the unavailability and high cost of antiviral drugs. It is important that physicians make a judicious treatment plan based on individual properties of each antiviral drug and the host’s immune status.

\section*{CONFLICTS OF INTEREST}

No potential conflict of interest relevant to this article was reported.

\section*{ACKNOWLEDGEMENTS}

This work was supported by a grant from Ministry of Health and Welfare, Republic of Korea (A102065).

\section*{REFERENCES}

1. Kim SB, Lee WK, Choi H, et al. A study on viral hepatitis markers and abnormal liver function test in adults living in northwest area of Chungnam. Korean J Gastroenterol 2009;53:355-360.
2. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227-242.
3. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-662.
4. DiBisceglie A, Lai CL, Gane E, et al. Telbivudine GLOBE trial: maximal early HBV suppression is predictive of optimal two-year efficacy in nucleoside treated hepatitis B patients. Hepatology 2006;44(Suppl 1):230A.
5. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73.
6. Iloeje UH, Yang HL, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130:678-686.
7. Zoulim F. Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection. Antiviral Res 2004;64:1-15.
8. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995;333:1657-1661.
9. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-1263.
10. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1999;339:61-68.
11. Schalm SW, Heathcote J, Giancana J, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000;46:562-568.
12. Chang TT, Lai CL, Chien RN, et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 2004;19:1276-1282.
13. Yao GB, Zhu M, Cui ZY, Wang BE, Yao JL, Zeng MD. A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China. J Dig Dis 2009;10:131-137.
14. Hadziyannis SJ, Papaioannidis G, Dimou E, Laras A, Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000;32(4 Pt 1):847-851.
15. Lok AS, Hussain M, Curtis C, et al. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy. Hepatology 2000;32:1145-1153.
16. Fung SK, Wong F, Hussain M, Lok AS. Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B. J Viral Hepat 2004;11:432-438.
17. Lee HJ, Eun R, Jang BI, Kim TN. Prevention by Lamivudine of hepatocellular carcinoma in patients infected with hepatitis B virus. Gut Liver 2007;1:151-158.
18. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-1531.
19. Nikolaidis N, Vassiliadis T, Gioumene O, et al. Effect of lamivudine
treatment in patients with decompensated cirrhosis due to anti-HBe positive/HBeAg-negative chronic hepatitis B. Clin Transplant. 2005;19:321-326.

36. Dienstag JL, Cianciara J, Karayalcin S, et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 2003;37:748-755.

37. Lee KM, Cho SW, Kim SW, Kim HJ, Halm KB, Kim JH. Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion. J Viral Hepat 2002;9:208-212.

38. Song BC, Suh DJ, Lee HC, Chung YH, Lee YS. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000;32(4 Pt 1):803-806.

39. Cha CK, Kwon HC, Cheong JY, et al. Association of lamivudine-resistant mutational patterns with the antiviral effect of adefovir in patients with chronic hepatitis B. J Med Virol 2009;81:417-424.

40. Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003;125:1714-1722.

41. Yuen MF, Sahlon E, Hui CK, Yuan HJ, Decraemter H, Lai CL. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001;34(4 Pt 1):785-791.

42. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-816.

43. Marcellin P, Chang TT, Lim SG, et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2008;48:750-758.

44. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBsAg-negative chronic hepatitis B. N Engl J Med 2005;352:2671-2681.

45. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003;348:800-807.

46. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ. Long-term therapy with adefovir dipivoxil for HBsAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006;131:1743-1751.

47. Lim SG, Marcellin P, Tassopoulos N, et al. Clinical trial: effects of adefovir dipivoxil therapy in Asian and Caucasian patients with chronic hepatitis B. Aliment Pharmacol Ther 2007;26:1419-1428.

48. Angus P, Vaughan R, Xiong S, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003;125:292-297.

49. Villeneuve JP, Durantel D, Durantel S, et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol 2003;39:1085-1089.

50. Westland CE, Yang H, Delaney WE 4th, et al. Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. Hepatology 2003;38:96-103.

51. Fung SK, Chae HB, Fontana RJ, et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 2006;44:283-290.
52. Heathcote EJ, Marcellin P, Buti M, et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011;140:132-143.
53. Liaw YF, Sheen IS, Lee CM, et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011;53:62-72.
54. van Bömmel F, de Man RA, Wedemeyer H, et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 2010;51:73-80.
55. Sheldon J, Camino N, Rodès B, et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther 2005;10:727-734.
56. Amini-Bavil-Olyaee S, Herbers U, Sheldon J, Luedde T, Trautwein C, Tacke F. The rTA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains. Hepatology 2009;49:1115-1165.
57. Balakrishna Pai S, Liu SH, Zhu YL, Chu CK, ChengYC. Inhibition of hepatitis B virus by a novel L-nucleoside, 2’-fluoro-5-methyl-beta-L-arabinofuranosyl uracil. Antimicrob Agents Chemother 1996;40:380-386.
58. Chu CK, Boudinot FD, Peek SF, et al. Preclinical investigation of L-FMAU as an anti-hepatitis B virus agent. Antivir Ther 1998;3(Suppl 3):113-121.
59. Ma T, Pai SB, Zhu YL, et al. Structure--activity relationships of 1-(2-Deoxy-2-fluoro-beta-L-arabinofuranosyl)pyrimidine nucleosides as anti-hepatitis B virus agents. J Med Chem 1996;39:2835-2843.
60. Yoo BC, Kim JH, Chung YH, et al. Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBcAg-positive chronic hepatitis B. Hepatology 2007;45:1172-1178.
61. Lau GK, Leung N. Forty-eight weeks treatment with clevudine 30 mg qd versus lamivudine 100 mg qd for chronic hepatitis B infection: a double-blind randomized study. Korean J Hepatol 2010;16:315-320.
62. Kim IH, Lee S, Kim SH, et al. Treatment outcomes of clevudine versus lamivudine at week 48 in naive patients with HBcAg positive chronic hepatitis B. J Korean Med Sci 2010;25:738-745.
63. Yoo BC, Kim JH, Kim TH, et al. Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression. Hepatology 2007;46:1041-1048.
64. Tak WY, Park SY, Cho CM, et al. Clinical, biochemical, and pathological characteristics of clevudine-associated myopathy. J Hepatol 2010;53:261-266.
65. Kim HJ, Park DI, Park JH, et al. Comparison between clevudine and entecavir treatment for antiviral-naive patients with chronic hepatitis B. Liver Int. 2010;30:834-840.
66. Kwon SY, Park YK, Ahn SH, et al. Identification and characterization of clevudine-resistant mutants of hepatitis B virus isolated from chronic hepatitis B patients. J Virol 2010;84:4494-4503.
67. Lee HJ, Eun JR, Lee CH, et al. Long-term clevudine therapy in nucleos(t)ide-naive and lamivudine-experienced patients with hepatitis B virus-related chronic liver diseases. Korean J Hepatol 2009;15:179-192.
68. Chang TT, Lai CL, Kew Yoon S, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010;51:422-430.
69. Suzuki F, Akuta N, Suzuki Y, et al. Efficacy of switching to entecavir monotherapy in Japanese lamivudine-pretreated patients. J Gastroenterol Hepatol 2010;25:892-898.
70. Yuen MF, Fung J, Seto WK, Wong DK, Yuen JC, Lai CL. Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy. Antivir Ther 2009;14:679-685.
71. Rapti I, Dimou E, Mitsoula P, Hadziyiannis SJ. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007;45:307-313.
72. Lampertico P, Viganò M, Manenti E, Iavarone M, Lunghi G, Colombo M. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 2005;42:1414-1419.
73. Lampertico P, Viganò M, Manenti E, Iavarone M, Sablon E, Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007;133:1445-1451.
74. Cho SW, Cho YJ, Cheong JY, et al. Add on lamivudine to adefovir monotherapy for the treatment of lamivudine-resistant chronic hepatitis B patients. Korean J Gastroenterol 2010;56:83-89.
75. van Bömmel F, Trojan J, Feucht HH, et al. Tenofovir shows limited efficacy in treatment of HBV infections resistant against adefovir. Hepatology 2007;46(Suppl 1):664A.
76. Patterson SJ, George J, Strasser SJ, et al. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut 2011;60:247-254.
77. Cho SW, Koh KH, Cheong JY, et al. Low efficacy of entecavir therapy in adefovir-refractory hepatitis B patients with prior lamivudine resistance. J Viral Hepat 2010;17:171-177.
78. Shim JH, Suh DJ, Kim KM, et al. Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone. Hepatology 2009;50:1064-1071.
79. Heo NY, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ. Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir. J Hepatol 2010;53:449-454.
80. Yang HJ, Lee JH, Kim YJ, Yoon JH, Lee HS. Lamivudine and adefovir dipivoxil versus entecavir 1.0 mg alone for the treatment of adefovir-resistant mutation which developed during sequential adefovir monotherapy in patients with lamivudine-resistant chronic hepatitis B. Korean J Hepatol 2009;15(Suppl 3):S50.